SOS for veno-occlusive disease: Defi brotide prophylaxis

The Lancet

Volumn 379, Issue 9823, 2012, Pages 1277-1278

  Platzbecker, Uwe ^a   Bornhäuser, Martin ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; DEFIBROTIDE; HEPARIN; URSODEOXYCHOLIC ACID;

BILIRUBIN BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; KIDNEY FAILURE; LIVER INJURY; LIVER VENOOCCLUSIVE DISEASE; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NOTE; PRIORITY JOURNAL; SINUSOIDAL OBSTRUCTION SYNDROME; WEIGHT GAIN;

EID: 84859430253     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60067-1     Document Type: Note

References (13)

1. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation-histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171-81.
2. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78-84. (Pubitemid 38029921)
3. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51: 1450-60.
4. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic venoocclusive disease after bone-marrow transplantation by continuous infusion of low-dose heparin-a prospective, randomized trial. Blood 1992; 79: 2834-40.
5. Gluckman E, Jolivet I, Scrobohaci ML, et al. Use of prostaglandin-E1 for prevention of liver venoocclusive disease in leukemic patients treated by allogeneic bone-marrow transplantation. Br J Haematol 1990; 74: 277-81. (Pubitemid 20106053)
6. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025-30. (Pubitemid 23293983)
7. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-83. (Pubitemid 35001226)
8. Richardson P, Linden E, Revta C, Ho V. Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol 2009; 2: 365-76.
9. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-29. (Pubitemid 32104928)
10. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16: 1005-17.
11. Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haematopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; published online Feb 23. DOI:10.1016/S0140-6736(11)61938-7.
12. Richardson P, Tomblyn M, Kernan N, et al. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control. Blood 2009; 114: 272-73.
13. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective Effect of defibrotide. Blood 2002; 100: 334-40. (Pubitemid 35177465)